Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;1(10):965-975.
doi: 10.1038/s43018-020-00120-5. Epub 2020 Sep 22.

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Laurence Albiges  1 , Stéphanie Foulon  2 , Arnaud Bayle  1 , Bertrand Gachot  3 , Fanny Pommeret  1   3 , Christophe Willekens  4 , Annabelle Stoclin  3 , Mansouria Merad  3 , Frank Griscelli  5 , Ludovic Lacroix  5 , Florence Netzer  6 , Thomas Hueso  4 , Corinne Balleyguier  7 , Samy Ammari  7 , Emeline Colomba  1 , Giulia Baciarello  1 , Audrey Perret  1 , Antoine Hollebecque  1   8 , Julien Hadoux  7 , Jean-Marie Michot  8 , Nathalie Chaput  4 , Veronique Saada  5 , Mathilde Hauchecorne  1 , Jean-Baptiste Micol  4 , Roger Sun  9 , Dominique Valteau-Couanet  10 , Fabrice André  1 , Florian Scotte  3 , Benjamin Besse  1 , Jean-Charles Soria  11 , Fabrice Barlesi  12   13
Affiliations

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Laurence Albiges et al. Nat Cancer. 2020 Oct.

Abstract

Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 patients managed for COVID-19 at the Gustave Roussy Cancer Centre, 125 (70.2%) were hospitalized, 47 (26.4%) developed clinical worsening and 31 (17.4%) died. An age of over 70 years, smoking status, metastatic disease, cytotoxic chemotherapy and an Eastern Cooperative Oncology Group score of ≥2 at the last visit were the strongest determinants of increased risk of death. In multivariable analysis, the Eastern Cooperative Oncology Group score remained the only predictor of death. In contrast, immunotherapy, hormone therapy and targeted therapy did not increase clinical worsening or death risk. Biomarker studies found that C-reactive protein and lactate dehydrogenase levels were significantly associated with an increased risk of clinical worsening, while C-reactive protein and D-dimer levels were associated with an increased risk of death. COVID-19 management impacted the oncological treatment strategy, inducing a median 20 d delay in 41% of patients and adaptation of the therapeutic strategy in 30% of patients.

PubMed Disclaimer

Comment in

References

    1. Liang, W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21, 335–337 (2020). - DOI
    1. Guan, W.-J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020). - DOI
    1. Grasselli, G. et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. J. Am. Med. Assoc. https://doi.org/10.1001/jama.2020.5394 (2020).
    1. Simpson, S. et al. Radiological society of North America expert consensus statement on reporting chest CT Findings related to COVID-19. Endorsed by the society of thoracic radiology, the American College of Radiology, and RSNA. J. Thorac. Imag. https://doi.org/10.1097/RTI.0000000000000524 (2020).
    1. Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. J. Am. Med. Assoc. https://doi.org/10.1001/jama.2020.6775 (2020).